Recombinant Anti-CD83 antibody [EPR23809-19] (ab275021)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR23809-19] to CD83
- Suitable for: Flow Cyt, IHC-P, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-CD83 antibody [EPR23809-19]
See all CD83 primary antibodies -
Description
Rabbit monoclonal [EPR23809-19] to CD83 -
Host species
Rabbit -
Tested applications
Suitable for: Flow Cyt, IHC-P, IPmore details
Unsuitable for: ICC/IF or WB -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- IHC-P: Human tonsil and Hodgkin's lymphoma tissue. Flow Cyt: HDLM-2 cells. IP: HDLM-2 whole cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR23809-19 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab275021 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
1/500.
|
|
IHC-P |
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
|
IP |
1/30.
|
Notes |
---|
Flow Cyt
1/500. |
IHC-P
1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
IP
1/30. |
Target
-
Function
May play a significant role in antigen presentation or the cellular interactions that follow lymphocyte activation. -
Tissue specificity
Expressed by activated lymphocytes, Langerhans cells and interdigitating reticulum cells. -
Sequence similarities
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 9308 Human
- Omim: 604534 Human
- SwissProt: Q01151 Human
- Unigene: 595133 Human
-
Alternative names
- B cell activation 45kDa cell surface glycoprotein Ig superfamily antibody
- B cell activation protein antibody
- B-cell activation protein antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD83 antibody [EPR23809-19] (ab275021)
Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling CD83 with ab275021 at 1/500 dilution followed by ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on human tonsil. The section was incubated with ab275021 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.
-
Flow cytometric analysis of HDLM-2 (Human Hodgkin lymphoma) cells labelling CD83 with ab275021 at 1/500 dilution (0.1µg) (Red) compared with a Rabbit monoclonal IgG (ab172730) (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue).
Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) at 1/2000 dilution was used as the secondary antibody.
Gated on viable cells.
-
CD83 was immunoprecipitated from 0.35 mg HDLM-2 (human hodgkin lymphoma) whole cell lysate with ab275021 at 1/30 dilution (2µg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab275021 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: HDLM-2 whole cell lysate 10 µg.
Lane 2: ab275021 IP in HDLM-2 whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab275021 in HDLM-2 whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 145 seconds.
The expression profile observed is consistent with what has been described in the literature (PMID: 15320871).
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD83 antibody [EPR23809-19] (ab275021)
Immunohistochemical analysis of paraffin-embedded human Hodgkin's lymphoma tissue labeling CD83 with ab275021 at 1/500 dilution followed by ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on human Hodgkin's lymphoma (PMID: 24633193). The section was incubated with ab275021 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (0)
ab275021 has not yet been referenced specifically in any publications.